BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 15300811)

  • 1. Frequent amplification and overexpression of CCND1 in male breast cancer.
    Bärlund M; Kuukasjärvi T; Syrjäkoski K; Auvinen A; Kallioniemi A
    Int J Cancer; 2004 Oct; 111(6):968-71. PubMed ID: 15300811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Invasive ductal carcinoma of the breast: study of the number of copies of the CCND1 gene and chromosome 11 using fluorescence in situ hybridization (FISH) in comparison with expression of cyclin D1 protein and estrogen receptors (ER alpha) with immunohistochemical detection].
    Mrhalová M; Kodet R; Strnad P
    Cas Lek Cesk; 2002 Nov; 141(22):708-14. PubMed ID: 12532908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer.
    Roy PG; Pratt N; Purdie CA; Baker L; Ashfield A; Quinlan P; Thompson AM
    Int J Cancer; 2010 Jul; 127(2):355-60. PubMed ID: 19904758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
    Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
    Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
    Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
    Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Her-2/neu gene amplification and protein expression in primary male breast cancer.
    Rudlowski C; Friedrichs N; Faridi A; Füzesi L; Moll R; Bastert G; Rath W; Büttner R
    Breast Cancer Res Treat; 2004 Apr; 84(3):215-23. PubMed ID: 15026619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic relevance of gene amplifications and coamplifications in breast cancer.
    Al-Kuraya K; Schraml P; Torhorst J; Tapia C; Zaharieva B; Novotny H; Spichtin H; Maurer R; Mirlacher M; Köchli O; Zuber M; Dieterich H; Mross F; Wilber K; Simon R; Sauter G
    Cancer Res; 2004 Dec; 64(23):8534-40. PubMed ID: 15574759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
    Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
    Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of ERBB2 gene status and chromosome 17 anomalies in male breast cancer.
    Fonseca RR; Tomás AR; André S; Soares J
    Am J Surg Pathol; 2006 Oct; 30(10):1292-8. PubMed ID: 17001161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paget's disease of the nipple: a copy number of the genes ERBB2 and CCND1 versus expression of the proteins ERBB-2 and cyclin D1.
    Mrhalova M; Kodet R
    Neoplasma; 2003; 50(6):396-402. PubMed ID: 14689059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers.
    Bizari L; Borim AA; Leite KR; Gonçalves Fde T; Cury PM; Tajara EH; Silva AE
    Cancer Genet Cytogenet; 2006 Feb; 165(1):41-50. PubMed ID: 16490596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic alterations in ERBB2-amplified breast carcinomas.
    Isola J; Chu L; DeVries S; Matsumura K; Chew K; Ljung BM; Waldman FM
    Clin Cancer Res; 1999 Dec; 5(12):4140-5. PubMed ID: 10632352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin D1 overexpression in Algerian breast cancer women: correlation with CCND1 amplification and clinicopathological parameters.
    Mohammedi L; Doula FD; Mesli F; Senhadji R
    Afr Health Sci; 2019 Jun; 19(2):2140-2146. PubMed ID: 31656498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
    Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
    Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis.
    Reis-Filho JS; Savage K; Lambros MB; James M; Steele D; Jones RL; Dowsett M
    Mod Pathol; 2006 Jul; 19(7):999-1009. PubMed ID: 16648863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer.
    Hui R; Campbell DH; Lee CS; McCaul K; Horsfall DJ; Musgrove EA; Daly RJ; Seshadri R; Sutherland RL
    Oncogene; 1997 Sep; 15(13):1617-23. PubMed ID: 9380415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer.
    Callari M; Cappelletti V; De Cecco L; Musella V; Miodini P; Veneroni S; Gariboldi M; Pierotti MA; Daidone MG
    Breast Cancer Res Treat; 2011 Jun; 127(3):601-10. PubMed ID: 20625818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival.
    Hui R; Ball JR; Macmillan RD; Kenny FS; Prall OW; Campbell DH; Cornish AL; McClelland RA; Daly RJ; Forbes JF; Blamey RW; Musgrove EA; Robertson JF; Nicholson RI; Sutherland RL
    Oncogene; 1998 Aug; 17(8):1053-9. PubMed ID: 9747885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
    Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.